Increased Proportions of Bifidobacterium and the Lactobacillus Group and Loss of Butyrate-Producing Bacteria in Inflammatory Bowel Disease

ABSTRACT Dysbiosis in the intestinal microbiota of persons with inflammatory bowel disease (IBD) has been described, but there are still varied reports on changes in the abundance of Bifidobacterium and Lactobacillus organisms in patients with IBD. The aim of this investigation was to compare the compositions of mucosa-associated and fecal bacteria in patients with IBD and in healthy controls (HCs). Fecal and biopsy samples from 21 HCs, 21 and 15 Crohn's disease (CD) patients, and 34 and 29 ulcerative colitis (UC) patients, respectively, were analyzed by quantitative real-time PCR targeting the 16S rRNA gene. The bacterial numbers were transformed into relative percentages for statistical analysis. The proportions of bacteria were uniformly distributed along the colon regardless of the disease state. Bifidobacterium was significantly increased in the biopsy specimens of active UC patients compared to those in the HCs (4.6% versus 2.1%, P = 0.001), and the proportion of Bifidobacterium was significantly higher in the biopsy specimens than in the fecal samples in active CD patients (2.7% versus 2.0%, P = 0.012). The Lactobacillus group was significantly increased in the biopsy specimens of active CD patients compared to those in the HCs (3.4% versus 2.3%, P = 0.036). Compared to the HCs, Faecalibacterium prausnitzii was sharply decreased in both the fecal and biopsy specimens of the active CD patients (0.3% versus 14.0%, P < 0.0001 for fecal samples; 0.8% versus 11.4%, P < 0.0001 for biopsy specimens) and the active UC patients (4.3% versus 14.0%, P = 0.001 for fecal samples; 2.8% versus 11.4%, P < 0.0001 for biopsy specimens). In conclusion, Bifidobacterium and the Lactobacillus group were increased in active IBD patients and should be used more cautiously as probiotics during the active phase of IBD. Butyrate-producing bacteria might be important to gut homeostasis.

[1]  R. Baldassano,et al.  Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis , 2009, The American Journal of Gastroenterology.

[2]  J. Fujimoto,et al.  Development of 16S rRNA-Gene-Targeted Group-Specific Primers for the Detection and Identification of Predominant Bacteria in Human Feces , 2002, Applied and Environmental Microbiology.

[3]  J. Doré,et al.  Biodiversity of the Mucosa‐Associated Microbiota Is Stable Along the Distal Digestive Tract in Healthy Individuals and Patients With Ibd , 2005, Inflammatory bowel diseases.

[4]  Anders F. Andersson,et al.  A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. , 2010, Gastroenterology.

[5]  J. Walter,et al.  Detection of Lactobacillus, Pediococcus, Leuconostoc, and Weissella Species in Human Feces by Using Group-Specific PCR Primers and Denaturing Gradient Gel Electrophoresis , 2001, Applied and Environmental Microbiology.

[6]  N. Pace,et al.  Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases , 2007, Proceedings of the National Academy of Sciences.

[7]  G. Macfarlane,et al.  Mucosa-Associated Bacterial Diversity in Relation to Human Terminal Ileum and Colonic Biopsy Samples , 2007, Applied and Environmental Microbiology.

[8]  J. Fujimoto,et al.  Use of 16S rRNA Gene-Targeted Group-Specific Primers for Real-Time PCR Analysis of Predominant Bacteria in Human Feces , 2004, Applied and Environmental Microbiology.

[9]  T. Klaenhammer,et al.  Genomic features of Lactobacillus species. , 2009, Frontiers in bioscience.

[10]  R Balfour Sartor,et al.  Microbial influences in inflammatory bowel diseases. , 2008, Gastroenterology.

[11]  T. Klaenhammer,et al.  Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid , 2011, Proceedings of the National Academy of Sciences.

[12]  Richard Hansen,et al.  Microbiota of De-Novo Pediatric IBD: Increased Faecalibacterium Prausnitzii and Reduced Bacterial Diversity in Crohn's But Not in Ulcerative Colitis , 2012, The American Journal of Gastroenterology.

[13]  M. Rescigno,et al.  Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model , 2012, Gut.

[14]  J. Doré,et al.  Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients , 2008, Proceedings of the National Academy of Sciences.

[15]  G. Holtrop,et al.  Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii , 2008, British Journal of Nutrition.

[16]  H. Kiyono,et al.  Probiotic Bifidobacterium breve Induces IL-10-Producing Tr1 Cells in the Colon , 2012, PLoS pathogens.

[17]  A. Gasbarrini,et al.  Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study , 2010, The American Journal of Gastroenterology.

[18]  A. Gasbarrini,et al.  Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[19]  Julian Parkhill,et al.  High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease , 2011, BMC Microbiology.

[20]  H. Lochs,et al.  Spatial Organization and Composition of the Mucosal Flora in Patients with Inflammatory Bowel Disease , 2005, Journal of Clinical Microbiology.

[21]  J. Walter,et al.  Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin‐10‐deficient mice , 2009, Inflammatory Bowel Diseases.

[22]  D. Haller,et al.  Post-Translational Inhibition of IP-10 Secretion in IEC by Probiotic Bacteria: Impact on Chronic Inflammation , 2009, PloS one.

[23]  A. Neish,et al.  REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY Microbes in Gastrointestinal Health and Disease , 2009 .

[24]  F. Shanahan,et al.  Culture-Independent Analyses of Temporal Variation of the Dominant Fecal Microbiota and Targeted Bacterial Subgroups in Crohn's Disease , 2006, Journal of Clinical Microbiology.

[25]  Y. Sanz,et al.  Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications , 2007, Clinical and experimental immunology.

[26]  R. Sartor.  Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[27]  S. Mazmanian,et al.  The gut microbiota shapes intestinal immune responses during health and disease , 2009, Nature Reviews Immunology.

[28]  A. Imaoka,et al.  Randomized placebo‐controlled trial assessing the effect of bifidobacteria‐fermented milk on active ulcerative colitis , 2004, Alimentary pharmacology & therapeutics.

[29]  A. Nusrat,et al.  Gastrointestinal , Hepatobiliary , and Pancreatic Pathology Probiotic Bacteria Induce Maturation of Intestinal Claudin 3 Expression and Barrier Function , 2012 .

[30]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[31]  S. Cucchiara,et al.  Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease , 2006, Gut.

[32]  A. Martí,et al.  Interplay Between Weight Loss and Gut Microbiota Composition in Overweight Adolescents , 2009, Obesity.

[33]  E. Zoetendal,et al.  Mucosa-Associated Bacteria in the Human Gastrointestinal Tract Are Uniformly Distributed along the Colon and Differ from the Community Recovered from Feces , 2002, Applied and Environmental Microbiology.

[34]  T. Hudcovic,et al.  Lysate of Probiotic Lactobacillus casei DN-114 001 Ameliorates Colitis by Strengthening the Gut Barrier Function and Changing the Gut Microenvironment , 2011, PloS one.

[35]  D. Rampton,et al.  Molecular Characterization of Rectal Mucosa‐Associated Bacterial Flora in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[36]  J. Doré,et al.  Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon , 2003, Gut.

[37]  M. Claesson,et al.  Antigen‐presenting cells exposed to Lactobacillus acidophilus NCFM, Bifidobacterium bifidum BI‐98, and BI‐504 reduce regulatory T cell activity , 2010, Inflammatory bowel diseases.

[38]  J. Garcia-Gil,et al.  Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction‐denaturing gradient gel electrophoresis , 2006, Inflammatory bowel diseases.

[39]  H. Buhr,et al.  Mucosal and Invading Bacteria in Patients with Inflammatory Bowel Disease Compared with Controls , 2002, Scandinavian journal of gastroenterology.

[40]  B. Kuster,et al.  Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. , 2012, Cell host & microbe.

[41]  B. Chassaing,et al.  The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. , 2011, Gastroenterology.

[42]  Janet K. Jansson,et al.  Twin studies reveal specific imbalances in the mucosa‐associated microbiota of patients with ileal Crohn's disease , 2009, Inflammatory bowel diseases.

[43]  M. Stolte,et al.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine , 2004, Gut.

[44]  M. Rescigno,et al.  Comparison of the Immunomodulatory Properties of Three Probiotic Strains of Lactobacilli Using Complex Culture Systems: Prediction for In Vivo Efficacy , 2009, PloS one.

[45]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[46]  L. Augenlicht,et al.  Inhibition of interferon γ signaling by the short chain fatty acid butyrate , 2003 .

[47]  L. Augenlicht,et al.  Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. , 2003, Molecular cancer research : MCR.

[48]  Manfred Dietel,et al.  Mucosal flora in inflammatory bowel disease. , 2002, Gastroenterology.